Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development

E. Schoultz, E. Johansson, C. Moccia, I. Jakubikova, N. Ravi, S. Liang, T. Carlsson, M. Montelius, K. Patyra, J. Kero, K. Paulsson, H. Fagman, MO. Bergo, M. Nilsson

. 2022 ; 15 (2) : . [pub] 20210811

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22019416

Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architecture modify tumorigenesis is unknown. Here, we characterized a new mouse model of sporadic thyroid carcinogenesis based on inducible expression of BRAF carrying a Val600 Glu (V600E) point mutation (BRAFV600E) from the thyroglobulin promoter (TgCreERT2). Spontaneous activation of this Braf-mutant allele due to leaky activity of the Cre recombinase revealed that intrinsic properties of thyroid follicles determined BRAF-mutant cell fate. Papillary thyroid carcinomas developed multicentrically within a normal microenvironment. Each tumor originated from a single follicle that provided a confined space for growth of a distinct tumor phenotype. Lineage tracing revealed oligoclonal tumor development in infancy and early selection of BRAFV600E kinase inhibitor-resistant clones. Somatic mutations were few, non-recurrent and limited to advanced tumors. Female mice developed larger tumors than males, reproducing the gender difference of human thyroid cancer. These data indicate that BRAFV600E-induced tumorigenesis is spatiotemporally regulated depending on the maturity and heterogeneity of follicles. Moreover, thyroid tissue organization seems to determine whether a BRAF-mutant lineage becomes a cancerized lineage. The TgCreERT2;BrafCA/+ sporadic thyroid cancer mouse model provides a new tool to evaluate drug therapy at different stages of tumor evolution.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019416
003      
CZ-PrNML
005      
20220804135633.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1242/dmm.048887 $2 doi
035    __
$a (PubMed)34379110
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Schoultz, Elin $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden
245    10
$a Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development / $c E. Schoultz, E. Johansson, C. Moccia, I. Jakubikova, N. Ravi, S. Liang, T. Carlsson, M. Montelius, K. Patyra, J. Kero, K. Paulsson, H. Fagman, MO. Bergo, M. Nilsson
520    9_
$a Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architecture modify tumorigenesis is unknown. Here, we characterized a new mouse model of sporadic thyroid carcinogenesis based on inducible expression of BRAF carrying a Val600 Glu (V600E) point mutation (BRAFV600E) from the thyroglobulin promoter (TgCreERT2). Spontaneous activation of this Braf-mutant allele due to leaky activity of the Cre recombinase revealed that intrinsic properties of thyroid follicles determined BRAF-mutant cell fate. Papillary thyroid carcinomas developed multicentrically within a normal microenvironment. Each tumor originated from a single follicle that provided a confined space for growth of a distinct tumor phenotype. Lineage tracing revealed oligoclonal tumor development in infancy and early selection of BRAFV600E kinase inhibitor-resistant clones. Somatic mutations were few, non-recurrent and limited to advanced tumors. Female mice developed larger tumors than males, reproducing the gender difference of human thyroid cancer. These data indicate that BRAFV600E-induced tumorigenesis is spatiotemporally regulated depending on the maturity and heterogeneity of follicles. Moreover, thyroid tissue organization seems to determine whether a BRAF-mutant lineage becomes a cancerized lineage. The TgCreERT2;BrafCA/+ sporadic thyroid cancer mouse model provides a new tool to evaluate drug therapy at different stages of tumor evolution.
650    _2
$a zvířata $7 D000818
650    12
$a protinádorové látky $7 D000970
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a bodová mutace $7 D017354
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a protoonkogenní proteiny B-raf $x genetika $x metabolismus $7 D048493
650    _2
$a papilární karcinom štítné žlázy $x genetika $x patologie $7 D000077273
650    12
$a nádory štítné žlázy $x genetika $x metabolismus $x patologie $7 D013964
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Johansson, Ellen $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden $1 https://orcid.org/000000034460065X
700    1_
$a Moccia, Carmen $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden $1 https://orcid.org/0000000332910589
700    1_
$a Jakubikova, Iva $u Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Ravi, Naveen $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund SE-22184, Sweden $1 https://orcid.org/0000000238498487
700    1_
$a Liang, Shawn $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden
700    1_
$a Carlsson, Therese $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden
700    1_
$a Montelius, Mikael $u Department of Radiology, Institute of Clinical Sciences, University of Gothenburg, SE-41345 Göteborg, Sweden $1 https://orcid.org/0000000191033446
700    1_
$a Patyra, Konrad $u Department of Endocrinology, University of Turku, Åbo FI-20521, Finland $1 https://orcid.org/0000000174582291
700    1_
$a Kero, Jukka $u Department of Endocrinology, University of Turku, Åbo FI-20521, Finland $1 https://orcid.org/0000000187677222
700    1_
$a Paulsson, Kajsa $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund SE-22184, Sweden $1 https://orcid.org/000000017950222X
700    1_
$a Fagman, Henrik $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden $u Department of Clinical Pathology, Sahlgrenska University Hospital, Göteborg SE-41345, Sweden $1 https://orcid.org/0000000158536295
700    1_
$a Bergo, Martin O $u Department of Biosciences and Nutrition, Karolinska Institute, Huddinge SE-14183, Sweden $1 https://orcid.org/0000000269157140
700    1_
$a Nilsson, Mikael $u Sahlgrenska Center for Cancer Research, Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, SE-40530 Göteborg, Sweden $1 https://orcid.org/0000000220093131
773    0_
$w MED00173721 $t Disease models & mechanisms $x 1754-8411 $g Roč. 15, č. 2 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34379110 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135627 $b ABA008
999    __
$a ok $b bmc $g 1822843 $s 1170659
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 15 $c 2 $e 20210811 $i 1754-8411 $m Disease models & mechanisms $n Dis Model Mech $x MED00173721
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options